Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    



Fighting Alzheimer's Head-on


 

Vanderbilt Research Could Redefine Alzheimer's Treatment

More than five million Americans are living with Alzheimer's disease, a diagnosis that kills more people yearly than breast and prostate cancers combined. Fortunately there's hope on the horizon, thanks to a number of studies and trials underway at Vanderbilt University Medical Center.

A potential new drug for Alzheimer's and schizophrenia developed by Vanderbilt University scientists was recently administered to the first volunteer at Vanderbilt Institute for Clinical and Translational Research. Animal studies suggest that the compound, a small molecule called VU319, may have potential for reducing memory impairments in brain disorders.


A Long Time Coming


Paul Newhouse, MD

"There's been an effort at Vanderbilt to develop new molecules for neuropsychiatric illnesses for several years," said Paul Newhouse, MD, director of the Vanderbilt Center for Cognitive Medicine.

The molecule was discovered several years ago at the Vanderbilt Center for Neuroscience Drug Discovery through a team of scientists led by center director Jeffrey Conn, PhD, and co-director Craig W. Lindsley, PhD.

"We realized this would be of particular interest for patients with Alzheimer's and began collaboration with Drs. Conn and Lindsley to try to move this drug from discovery into human trials," Newhouse said. "It's one thing to discover a new molecule and test it in rats, but it's another to get approval to put a new drug into humans."

The molecule received FDA approval for human trials November 2016 and began the first-in-human Phase 1 clinical trial in July. "This is a novel achievement because we're the first university to go from molecular discovery to testing in humans in the same university for a new potential Alzheimer's disease treatment," said Newhouse. Once a molecule is discovered, he explained, schools typically license it to a commercial entity to help defray development costs.

Trial Opportunities

Enrollment is still open for the randomized double-blind, placebo-controlled study, which will be conducted in approximately 100 healthy adult volunteers over the next year. The single dose cohort, which concludes next spring, will help determine the compound's safety, tolerability and bioavailability when taken orally. Dosage will gradually be increased in participants until it reaches the highest level of exposure previously administered in animals.

Trial participants undergo testing for brain effects using sophisticated computerized cognitive testing and EEG. While the molecule isn't a cure for Alzheimer's, it's expected to enhance attention, memory and learning earlier than ever.

"We've known for years that a certain chemical system is deficient in patients with Alzheimer's so medications typically try to enhance that indirectly," said Newhouse. The new molecule attempts to directly stimulate that system in a way that's never been done and could be used independently or as a complimentary therapy. Newhouse also believes it could be administered at the onset of symptoms to help slow progression of the disease.

Alzheimer's Treatment Past & Present

Historically, innovation in Alzheimer's therapies has been remarkably slow, with a failure rate of over 99 percent. In fact, the last FDA approved Alzheimer's drug was introduced some 15 years ago.

"There's still a lot we don't know about Alzheimer's, and that's disconcerting to us," said Newhouse. "We thought we understood the biology, but it's more complex than we thought."

That's because the predominant theory of what's causing the illness might be true ... but changing those proteins doesn't necessarily alter symptoms. Still, researchers are hopeful about the molecule's cognitive benefits due to promising evidence from preclinical studies.

VU319 isn't the only potential game-changer coming out of Vanderbilt. "We're doing a lot here in terms of clinical trials in Alzheimer's patients with new therapies, including collaborating with pharmaceutical companies," he said. "We're focused on early stage, as well as prevention."

Newhouse also is the national lead investigator for a 27-site study through the National Institute on Aging. The Memory Improvement Through Nicotine Dosing study uses transdermal nicotine patches to enhance early memory loss. The MIND study is a collaboration between Vanderbilt and the University of Southern California's Alzheimer's Therapeutic Research Institute.

Another NIA study, the Alzheimer's Disease Neuroimaging Initiative, looks at history, biomarkers and symptoms to better distinguish between dementia and Alzheimer's. Participants receive specialized scans and spinal fluid analysis not available to the general public.

"Not every dementia is Alzheimer's, and it's important for any family to make sure they get an accurate diagnosis," Newhouse said. "Seniors are living longer, and brain health is becoming ever more critical. The sad reality is that the percentage of patients diagnosed is increasing, although it's better recognized than it used to be."


Protecting the Brain

Newhouse also wants to dispel common myths related to aging. "There's a belief that as you get older memory inevitably becomes worse, but that's not true," Newhouse said. "The brain is not immune to age-related changes, but brain function overall should not decline." To that end, lifestyle choices are now recognized as an increasingly important aspect of protecting brain function during aging.

"There's no question that paying attention to lifestyle will make a significant dent in dementia outcomes," Newhouse said. "We can't prevent it, but we know we can do a lot to reduce risk; and we're beginning to think about ways we can help younger and middle age people reduce their risk earlier in life. Identifying those at increased risk is something I'm quite passionate about, and it's being seen as a new approach to treating this disease."


WEB:

VUMC

Vanderbilt Center for Cognitive Medicine

Vanderbilt Center for Neuroscience Drug Discovery

 
Share:

Related Articles:


Recent Articles

Senate HELP Committee Hearing on Gene Editing Technology

On Nov. 14, the Senate health committee held a hearing on the gene editing method CRISPR to learn more about the technology from expert witnesses, which included Dr. Matthew Porteus, associate professor of Pediatrics at Stanford University; Katrine Bosley, CEO and president of Editas Medicine; and Dr. Jeffrey Kahn, director of the Johns Hopkins Berman Institute of Bioethics at Johns Hopkins School of Public Health.

Read More

Nashville Health Care Council Hosts Panel Discussion on Pharma/Provider Collaborations in Health Care

On Nov. 13, the Nashville Health Care Council hosted a panel discussion on collaborations between the pharmaceutical and healthcare provider sectors and how those collaborations can drive change in healthcare.

Read More

Tennessee Health Care Hall of Fame Class of 2017

Six healthcare luminaries were recently inducted into the Tennessee Health Care Hall of Fame.

Read More

NMGMA 10 Minute Takeaway

Nashville Medical News recently had the opportunity to chat with new NMGMA president Joy Testa.

Read More

Tennessee Joins Medical Licensing Compact

A new Tennessee law will make it easier for area physicians to practice across state lines beginning in 2019 as part of the Interstate Medical Licensure Compact.

Read More

A Plan to Address COPD

COPD is the third leading cause of death in America, yet it lags behind many other conditions in terms of research dollars and coordinated federal response ... but that seems to be changing.

Read More

Surgical Innovations

Two new procedures recently made their debut in Middle Tennessee offering new treatment options for coronary bifurcation lesions and lumbar fusion.

Read More

Don't fear the FBAR

If you are a taxpayer with offshore financial accounts, you could be in trouble with the IRS and not even know it.

Read More

HoneyCo Homes: Using Smart Technology to Help Seniors Age in Place

A Nashville startup is using technology to help seniors age in place while providing peace of mind to loved ones and actionable data to caregivers.

Read More

A Better Continuum Means Better Care

As the U.S. population ages, new partnerships along the continuum of care are necessary to achieve optimal outcomes for patients.

Read More

Email Print
 
 

 

 


Tags:
Alzheimer's, Craig W. Lindsley, Dementia, Jeffrey Conn, Paul Newhouse, Schizophrenia, Senior Health, Vanderbilt Center for Cognitive Medicine, Vanderbilt Center for Neuroscience Drug Discovery, VU319
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: